Optimization of Large-Scale Expansion and Cryopreservation of Human Natural Killer Cells for Anti-Tumor Therapy
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Allogeneic natural killer (NK) cell therapy is a potential therapeutic approach for a variety of solid tumors. We established an expansion method for large-scale production of highly purified and functionally active NK cells, as well as a freezing medium for the expanded NK cells. In the present study, we assessed the effect of cryopreservation on the expanded NK cells in regards to viability, phenotype, and anti-tumor activity. NK cells were enormously expanded (about 15,000-fold expansion) with high viability and purity by stimulating CD3+ T cell-depleted peripheral blood mononuclear cells (PBMCs) with irradiated autologous PBMCs in the presence of IL-2 and OKT3 for 3 weeks. Cell viability was slightly reduced after freezing and thawing, but cytotoxicity and cytokine secretion were not significantly different. In a xenograft mouse model of hepatocellular carcinoma cells, cryopreserved NK cells had slightly lower anti-tumor efficacy than freshly expanded NK cells, but this was overcome by a 2-fold increased dose of cryopreserved NK cells. In vivo antibody-dependent cell cytotoxicity (ADCC) activity of cryopreserved NK cells was also demonstrated in a SCID mouse model injected with Raji cells with rituximab co-administration. Therefore, we demonstrated that expanded/frozen NK cells maintain viability, phenotype, and anti-tumor activity immediately after thawing, indicating that expanded/frozen NK cells can provide ‘ready-to-use’ cell therapy for cancer patients.
Abstract
Allogeneic natural killer (NK) cell therapy is a potential therapeutic approach for a variety of solid tumors. We established an expansion method for large-scale production of highly purified and functionally active NK cells, as well as a freezing medium for the expanded NK cells. In the present study, we assessed the effect of cryopreservation on the expanded NK cells in regards to viability, phenotype, and anti-tumor activity. NK cells were enormously expanded (about 15,000-fold expansion) with high viability and purity by stimulating CD3+ T cell-depleted peripheral blood mononuclear cells (PBMCs) with irradiated autologous PBMCs in the presence of IL-2 and OKT3 for 3 weeks. Cell viability was slightly reduced after freezing and thawing, but cytotoxicity and cytokine secretion were not significantly different. In a xenograft mouse model of hepatocellular carcinoma cells, cryopreserved NK cells had slightly lower anti-tumor efficacy than freshly expanded NK cells, but this was overcome by a 2-fold increased dose of cryopreserved NK cells. In vivo antibody-dependent cell cytotoxicity (ADCC) activity of cryopreserved NK cells was also demonstrated in a SCID mouse model injected with Raji cells with rituximab co-administration. Therefore, we demonstrated that expanded/frozen NK cells maintain viability, phenotype, and anti-tumor activity immediately after thawing, indicating that expanded/frozen NK cells can provide ‘ready-to-use’ cell therapy for cancer patients.
참고문헌 (27)
- Lanier LL, "Natural killer cells: definition of a cell type rather than a function", J Immunol, 137, pp.2735~2739 (1986)
- Robertson MJ, "Biology and clinical relevance of human natural killer cells", Blood, 76, pp.2421~2438 (1990)
- Beano A, "Correlation between NK function and response to trastuzumab in metastatic breast cancer patients", J Transl Med, 6, pp.25~ (2008)[DOI]
- Trapani JA, "Functional significance of the perforin", granzyme cell death pathway, 2002, pp.2, 735~747
- Deauvieau F, "Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells", Int J Cancer, 136, pp.1085~1094 (2015)[DOI]
- Lim O, "Present and future of allogeneic natural killer cell therapy", Front Immunol, 6, pp.286~ (2015)
- Miller JS, "Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer", Blood, 105, pp.3051~3057 (2005)[DOI]
- Iliopoulou EG, "A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer", Cancer Immunol Immunother, 59, pp.1781~1789 (2010)[DOI]
- Krause SW, "Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial", Clin Cancer Res, 10, pp.3699~3707 (2004)[DOI]
- Geller MA, "A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer", Cytotherapy, 13, pp.98~107 (2011)[DOI]
- Yang Y, "Phase I study of random healthy donor-derived allogeneic natural killer cell therapy in patients with malignant lymphoma or advanced solid tumors", Cancer Immunol Res, 4, pp.215~224 (2016)[DOI]
- Lim O, "GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo", PLoS One, 8, pp.e53611~ (2013)[DOI]
- Lundqvist A, "Bortezomib treatment to potentiate the anti-tumor immunity of ex-vivo expanded adoptively infused autologous natural killer cells", J Cancer, 2, pp.383~385 (2011)[DOI]
- Denman CJ, "Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells", PLoS One, 7, pp.e30264~ (2012)[DOI]
- Lapteva N, "Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications", Cytotherapy, 14, pp.1131~1143 (2012)[DOI]
- Berg M, "Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells", Cytotherapy, 11, pp.341~355 (2009)[DOI]
- Torelli GF, "A good manufacturing practice method to ex vivo expand natural killer cells for clinical use", Blood Transfus, 13, pp.464~471 (2015)
- Miller JS, "Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy", Biol Blood Marrow Transplant, 20, pp.1252~1257 (2014)[DOI]
- Szmania S, "Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients", J Immunother, 38, pp.24~36 (2015)[DOI]
- Neri S, "Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants", Clin Diagn Lab Immunol, 8, pp.1131~1135 (2001)
- Ruggeri L, "Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants", Science, 295, pp.2097~2100 (2002)[DOI]
- Holubova M, "Cryopreserved NK cells in the treatment of haematological malignancies: preclinical study", J Cancer Res Clin Oncol, 142, pp.2561~2567 (2016)[DOI]
- Klingemann H, "Challenges of cancer therapy with natural killer cells", Cytotherapy, 17, pp.245~249 (2015)[DOI]
- Mentlik James A, "Combination immune therapies to enhance anti-tumor responses by NK cells", Front Immunol, 4, pp.481~ (2013)
- Battella S, "Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions", J Leukoc Biol, 99, pp.87~96 (2016)[DOI]
- Weiner GJ, "Rituximab: mechanism of action", Semin Hematol, 47, pp.115~123 (2010)[DOI]
- Hallek M, "Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial", Lancet, 376, pp.1164~1174 (2010)[DOI]